PARIS: Interruption of dual antiplatelet treatment can be safe depending on the clinical context and treatment time

The cessation of dual antiplatelet treatment increased the risk of post coronary intervention adverse events. It is unclear whether the risk varies through time or if it depends on the reason for the interruption or both.

The PARIS (patterns of non-adherence to anti-platelet regimens in stented patients) register is a prospective, observational study in patients who received coronary angioplasty between 2009 and 2010. The prespecified categories for the interruption of dual antiplatelet treatment were: medical advice, brief interruption (for surgical procedure) resuming within 14 days, and interruption (due to bleeding or lack of adherence). Included in the register were 5031 patients who underwent angioplasty in which the general incidence of treatment interruption at 2 years was 57.3%. Interruption on medical advice was 40.8%, temporary interruption 10.5% and interruption due to adverse effects or lack of adherence was 14.4%.

The general incidence of adverse effects was 11.5%, the majority (74%) occurring while patients were on the dual scheme. Compared with patients who were on dual antiplatelet treatment, the risk of events from temporary interruption was 1.4 (p=0.1) and interruption due to adverse effects or lack of adherence, 1.5 (p=0.004). Within 7, 8 and 30 days and beyond 30 days the adjusted rates were 7.04 (3.31 – 14.95), 2.17 (0.97 – 4.88) and 1.3 (0.97 – 1.76) respectively.

Conclusion:

Interruption of dual antiplatelet treatment is safe when medically indicated and when it must be temporarily suspended for a procedure. However, when the interruption is due to bleeding the relative risk of events is 50% higher and produced primarily in the first 7 days.

Read editorial

Read article

Roxana%20Mehran_slides
Roxana Mehran
2013-09-02

Original title: Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.

More articles by this author

INTIME: Home monitoring of severe heart failure patients gives promising results.

Rehospitalization or death due to worsening heart failure is often preceded by changes in clinical parameters, weight or arrhythmias. The home monitoring device has...

DECAAF: Pre ablation magnetic resonance in patients with atrial fibrillation is capable of detecting the degree of fibrosis and predicting the success of...

260 patients with atrial fibrillation were included who underwent nuclear magnetic resonance 30 days before ablation and 90 days following. The patients were classified...

PRAGUE 14: Anti-thrombotic therapy before non-cardiac surgery may be associated with a higher incidence of bleeding.

The majority of coronary patients are under anti-thrombotic therapy and its interruption may increase cardiovascular risk, while on the other hand, continuation during a...

LINC: The LUCAS device failed to demonstrate benefit in cardiac arrest patients.

Each year between 300,000 and 400,000 people suffer an out-of-hospital heart attack in Europe. Only between 5% and 7% of these patients survive and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...